君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

休市中 10-16 16:08:16

16.310

+0.130

+0.80%

最高16.890	最低16.140	成交量120.84万
今开16.450	昨收16.180	日振幅4.64%
总市值167.50亿	流通市值42.41亿	总股本10.27亿
成交额2,002万	换手率0.46%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":16.31,"timestamp":1792138096004,"preClose":16.18,"halted":0,"volume":1208400,"delay":0,"changeRate":0.00803461063040785,"floatShares":260000000,"shares":1027000000,"eps":-0.87,"marketStatus":"休市中","change":0.13,"latestTime":"10-16 16:08:16","open":16.45,"high":16.89,"low":16.14,"amount":20018108,"amplitude":0.046354,"askPrice":16.45,"askSize":1400,"bidPrice":16.31,"bidSize":4600,"shortable":3,"etf":0,"ttmEps":-0.451,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":16.18,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":0.8682406701210547,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物-U","latestPrice":29.97,"timestamp":1792134000000,"preClose":30.07,"halted":0,"volume":12362500,"delay":0,"premium":"-53.63"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2675542315","title":"生物医药板块走强 康诺亚-B（02162）涨9.00%、金斯瑞生物科技（01548）涨7.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675542315","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675542315?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:37","pubTimestamp":1792114658,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走强，康诺亚-B 涨9.00%，金斯瑞生物科技涨7.53%，百济神州涨5.38%，科伦博泰生物涨5.25%，再鼎医药涨4.46%，君实生物涨3.71%，泰格医药涨3.65%，复宏汉霖涨2.99%。中信建投证券表示，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993835","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","HK0000320264.USD","LU2488822045.USD","LU0828237510.HKD","LU1969619763.USD","BK1576","06990","LU1303224171.USD","XBI","BK4581","LU1251922891.USD","LU0307460666.USD","HK0000320223.HKD","02696","BK1583","01877","BK1588","06160","HK0000165453.HKD","HK0000306685.HKD","LU0588546209.SGD","BK1587","LU1719994722.HKD","01548","LU1770034418.SGD","BK1574","BK4585","HK0000306701.USD","399441","LU0196878994.USD","BK1500","LU0228659784.USD","161726","BK1515","02162","09688","LU2328871848.SGD","KURE","BK4588","BK1161","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675546035","title":"【券商聚焦】中信建投：ESMO中国研究入选创新高 梳理医药细分板块机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2675546035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675546035?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:27","pubTimestamp":1792114033,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示，本周制药行业表现一般，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医疗器械及服务板块低值耗材表现较好，多受个股事件催化，科技概念标的调整，港股回购活跃；短期关注招标改善和集采出清，中长期看创新、出海、并购。中药板块跑赢申万医药及大盘，关注红利、创新及“四同药品”、中成药集采政策。生物制品板块跑输医药指数及大盘，AI制药、mRNA肿瘤疫苗概念股回调；南北方ILI%均环比降低，南方检测阳性率提升、北方降低。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993829","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","09926","01177","LU0228659784.USD","SG9999011746.SGD","01877","09688","02616","601066","BK1500","LU1226287792.SGD","02269","LU0823426480.USD","LU1251922891.USD","LU0140636845.USD","LU0819121731.USD","BK1610","LU0181495838.USD","06160","BK1515","LU0540923850.HKD","LU0052750758.USD","BK1583","LU0979878070.USD","SG9999002562.SGD","LU1226287875.USD","LU0072913022.USD","BK1141","LU0348827113.USD","01801","09995","09939","02142","LU0501845795.SGD","LU1951186391.HKD","LU0417516902.SGD","06185","KCE","LU2476274720.SGD","LU0326950275.SGD","LU1969619763.USD","159938","IE00BZ08YR35.GBP","LU0128526141.USD","LU0348767384.USD","LU0634319403.HKD","LU1242518857.USD","LU0359201612.USD","LU0314109678.HKD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675531105","title":"股市必读：君实生物新发布《君实生物H股公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675531105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675531105?lang=zh_cn&edition=full","pubTime":"2026-10-16 01:19","pubTimestamp":1792084748,"startTime":"0","endTime":"0","summary":"截至2026年10月15日收盘，君实生物报收于30.07元，下跌1.22%，换手率1.42%，成交量10.86万手，成交额3.31亿元。当日关注点交易信息汇总：10月15日主力资金净流入1577.38万元，占总成交额4.77%。公司公告汇总君实生物H股公告上海君实生物医药科技股份有限公司董事会谨定于2026年10月29日举行董事会会议，以考虑及通过本集团截至2026年9月30日止9个月未经审核的财务业绩。公告日期为2026年10月15日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600002003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1515","BK1161","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163152165","title":"君实生物将于10月29日审议2026年前九个月未经审计业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1163152165","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163152165?lang=zh_cn&edition=full","pubTime":"2026-10-15 17:06","pubTimestamp":1792055177,"startTime":"0","endTime":"0","summary":"君实生物（01877）10月15日在港交所披露公告称，公司董事会已决定于2026年10月29日（星期四）召开会议，审议并通过集团截至2026年9月30日止9个月的未经审计财务业绩。同时，董事会将处理其他相关事项。根据公告披露，会议由董事长熊俊先生主持。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675376082","title":"【券商聚焦】中信建投：AI重塑药物研发 2035年全球市场有望破460亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675376082","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675376082?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:00","pubTimestamp":1792026019,"startTime":"0","endTime":"0","summary":"AI深度介入靶点识别、分子设计等药物研发环节，破解传统制药高投入、长周期难题。报告测算，全球AI制药市场2025年规模约24.9亿美元，2035年有望突破460亿美元，CAGR超33%，国内市场具备高增长潜力；科技巨头、药企、CXO等多方入局，海内外多家头部企业完成平台搭建与商业化验证。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993729","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU1152091754.HKD","02269","LU0501845795.SGD","LU0052750758.USD","LU0128526141.USD","LU0128522744.USD","LU0456827905.SGD","01801","BK1576","IE00B031HY20.USD","01877","LU0456846285.SGD","LU0979878070.USD","LU0326950275.SGD","02616","LU2242644610.SGD","IBBJ","LU0029874061.USD","LU0588546209.SGD","LU0516422440.USD","BK1588","601066","VTHR","LU0856984785.SGD","LU0051755006.USD","LU1008478684.HKD","06185","09688","09926","01093","AIPO","02142","KCE","LU1251922891.USD","CHAT","LU0516422952.EUR","AGIX","SG9999002562.SGD","BK1500","BK1141","LU2778985437.USD","09995","KURE","IE00BZ08YS42.EUR","ARTY","01177","06160","QTOC","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674403873","title":"破发股君实生物跌3.69% 国泰海通保荐上市2募资共86亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2674403873","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674403873?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:12","pubTimestamp":1791796342,"startTime":"0","endTime":"0","summary":"中国经济网北京10月12日讯 君实生物  今日收报32.58元，跌幅3.69%。该股目前处于破发状态。　　上市首日，君实生物股价最高报220.40元，为上市以来股价最高点。　　君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿元，较原计划多17.97亿元。　　君实生物首次公开发行股票发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。　　经计算，君实生物两次募集资金合计86.12亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20261012/32393819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1564","BK0184","BK0188","BK0201","BK1161","BK0012","601211","BK1583","01877","BK0183","BK1515","BK0276","BK1147","BK0028","02611","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674967889","title":"君实生物（688180）10月8日主力资金净卖出7288.65万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674967889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674967889?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:30","pubTimestamp":1791505856,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，君实生物报收于33.42元，下跌6.28%，换手率2.56%，成交量19.64万手，成交额6.71亿元。10月8日的资金流向数据方面，主力资金净流出7288.65万元，占总成交额10.86%，游资资金净流入2370.04万元，占总成交额3.53%，散户资金净流入4918.6万元，占总成交额7.33%。融券方面，融券卖出0.0股，融券偿还2963.0股，融券余量30.35万股，融券余额1014.14万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","BK1515","BK0239","01877","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673802237","title":"破发股君实生物跌6.28% 国泰君安保荐上市2募资共86亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2673802237","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673802237?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:12","pubTimestamp":1791447139,"startTime":"0","endTime":"0","summary":"中国经济网北京10月8日讯 君实生物 今日收报33.42元，跌幅6.28%。该股目前处于破发状态。　　上市首日，君实生物股价最高报220.40元，为上市以来股价最高点。　　君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿元，较原计划多17.97亿元。　　君实生物首次公开发行股票发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。　　经计算，君实生物两次募集资金合计86.12亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20261008/32390151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","IPOS","BK1161","BK1583","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673012072","title":"股市必读：君实生物新发布《君实生物H股公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673012072","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673012072?lang=zh_cn&edition=full","pubTime":"2026-10-08 02:35","pubTimestamp":1791398111,"startTime":"0","endTime":"0","summary":"公司公告汇总君实生物H股公告上海君实生物医药科技股份有限公司截至2026年9月30日的证券变动月报表显示，公司H股和A股的法定/注册股本、已发行股份及库存股均无变动。H股于港交所上市，A股于上交所科创板上市。当月未发生股份期权行使、权证发行或可换股票据转换。确认公众持股量符合上市规则要求，且所有证券发行均已获董事会授权并遵守相关法规。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800001309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","BK1583","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673033818","title":"生物医药板块走高 恒生生物科技指数涨2.32% 金斯瑞生物科技（01548）涨5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673033818","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673033818?lang=zh_cn&edition=full","pubTime":"2026-10-06 10:01","pubTimestamp":1791252073,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走高，恒生生物科技指数涨2.32%，恒生医疗保健指数涨2.19%，万得中国创新药指数涨2.15%。个股方面，再鼎医药涨6.97%，金斯瑞生物科技涨5.30%，君实生物涨3.07%，药明生物涨3.07%，康方生物涨2.92%，康诺亚-B涨2.33%，泰格医药涨1.90%，诺诚健华涨1.87%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MGY1NDA5NTM4NDQ4Mw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGY1NDA5NTM4NDQ4Mw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993104","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0039217434.USD","LU0348784397.USD","LU0516422952.EUR","HK0000306701.USD","LU0320764599.SGD","161726","LU0128522744.USD","01548","XBI","LU0051755006.USD","LU2778985437.USD","IE00BPRC5H50.USD","03347","LU0516423174.USD","02269","LU1794554557.SGD","LU0307460666.USD","BK1141","LU0708995583.HKD","LU0181495838.USD","SG9999002562.SGD","LU0359202008.SGD","BK4581","KURE","399441","01877","LU0052750758.USD","09688","BK1515","LU0140636845.USD","BK1574","LU0417516902.SGD","LU0456827905.SGD","LU0327786744.USD","LU0561508036.HKD","LU0634319403.HKD","LU2488822045.USD","SG9999002463.SGD","LU0348735423.USD","HK0000320223.HKD","02162","LU0708995153.HKD","LU1880383366.USD","09926","LU1242518857.USD","LU1720050803.USD","09969","LU2039709279.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109052102","title":"君实生物9月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1109052102","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109052102?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:38","pubTimestamp":1791189491,"startTime":"0","endTime":"0","summary":"2026年10月5日，上海君实生物医药科技股份有限公司披露截至2026年9月30日的证券变动月报。报告显示，H股注册股本260,295,700股，A股注册股本766,394,171股，总注册股本1,026,689,871股，均较上月无变化。本月内公司未出现新增发行股份、购回或注销情况，已发行股份总数保持不变。A股股票期权激励计划则本月实际授予715,000份，同时注销1,740,000份，剩余100,871份期权不再授予并失效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673792787","title":"【券商聚焦】国金证券：行业有望迎业绩与估值戴维斯双击，创新药板块底部配置价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2673792787","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673792787?lang=zh_cn&edition=full","pubTime":"2026-10-05 08:50","pubTimestamp":1791161445,"startTime":"0","endTime":"0","summary":"随着后续管线商业化兑现、全球创新价值链话语权提升，行业有望迎来业绩与估值的戴维斯双击，创新药板块底部配置价值凸显。中国研究占全体大会核心LBA总量的1/3，这标志着中国肿瘤创新研发已深度融入全球研发体系，成为驱动全球肿瘤诊疗升级的重要力量，持续利好国内创新药企国际化发展与临床价值兑现。2026 ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992996","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","BK1610","HK0000165453.HKD","LU1807302812.USD","01801","LU0244354667.USD","LU0516422952.EUR","01177","09688","09926","01093","BK1583","LU0314109678.HKD","02142","LU0540923850.HKD","MEDX","LU1242518931.SGD","BK1576","IE0008368742.USD","LU0823426480.USD","IE00BPRC5H50.USD","LNGR","LU1794554557.SGD","06160","02616","LU0043850808.USD","LU2399975544.HKD","LU0823426308.USD","IBBQ","LU1328277881.USD","LU0052750758.USD","LU1226287875.USD","159992","01877","LU1226288253.USD","LU2242644610.SGD","KURE","09995","600109","BK0201","02269","06978","KCE","LU0315179316.USD","LU0359202008.SGD","LU0455707207.USD","BK1161","BK1515","LU0856984785.SGD","LU0211977185.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673805779","title":"君实生物获BNP PARIBAS SA增持20.48万股 每股作价17.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673805779","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673805779?lang=zh_cn&edition=full","pubTime":"2026-10-05 07:59","pubTimestamp":1791158340,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，9月28日，BNP PARIBAS SA增持君实生物（01877）20.48万股，每股作价17.96港元，总金额约为367.82万港元。增持后最新持股数目为2354.56万股，最新持股比例为9.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-10-05/doc-iniucpwp9792434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","BK1583","EWH","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672712116","title":"BNP PARIBAS SA增持君实生物(01877.HK)20.48万股 每股作价17.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2672712116","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672712116?lang=zh_cn&edition=full","pubTime":"2026-10-02 20:52","pubTimestamp":1790945558,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01877","BK1161","BK1515","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172866622","title":"君实生物：BNP PARIBAS SA增持，好仓比例升至9.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172866622","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172866622?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:33","pubTimestamp":1790933606,"startTime":"0","endTime":"0","summary":"BNP PARIBAS SA于2026年9月28日在联交所场内以每股均价17.96港元买入君实生物20.48万股，涉资约367.82万港元，属场内主动交易，即在二级市场直接买卖股份。BNP PARIBAS SA此次增持前持有君实生物好仓2334.08万股，占比8.97%；增持后持股量为2354.56万股，好仓比例升至9.05%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671224513","title":"港股异动 | 君实生物(01877)涨超4% 与美杰医疗达成战略合作 探索肿瘤治疗“多模态药械联用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2671224513","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671224513?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:42","pubTimestamp":1790736130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物涨超4%，截至发稿，涨4.03%，报19.09港元，成交额2326.84万港元。消息面上，据君实生物官微消息，公司宣布与美杰医疗于近日正式签署战略合作协议，双方将围绕“多模态热物理免疫调控平台技术与药物联合临床研究、新药靶点探索”等核心方向展开全方位战略合作，引领肿瘤治疗迈向“多模态药械联用”的新时代。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","CANC","CNCR","LU2488822045.USD","BK4588","BK1583","BK4585","LU0737861772.HKD","06078","01877","BK1515","LU0329678337.USD","LU0329678170.USD","BK1209","159891","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671985492","title":"君实生物等在嘉兴成立股权投资合伙企业 出资额3.6亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2671985492","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671985492?lang=zh_cn&edition=full","pubTime":"2026-09-29 12:27","pubTimestamp":1790656020,"startTime":"0","endTime":"0","summary":"南方财经9月29日电，天眼查App显示，近日，嘉兴源禾创孚股权投资合伙企业（有限合伙）成立，执行事务合伙人为君实创业投资（海南）有限公司，出资额3.6亿元，经营范围为以私募基金从事股权投资、投资管理、资产管理等活动，创业投资。合伙人信息显示，该合伙企业由海盐县国有资本投资运营有限公司、上海君实生物医药科技股份有限公司、海盐嘉睿战新股权投资合伙企业（有限合伙）等共同出资。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886340585.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886340585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877","BK1161","BK1583","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670235064","title":"君实生物（688180）披露2026年中期报告，9月28日股价下跌0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670235064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670235064?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:57","pubTimestamp":1790589437,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，君实生物报收于34.84元，较前一交易日下跌0.11%，最新总市值为357.7亿元。该股当日开盘35.31元，最高35.63元，最低34.39元，成交额达3.99亿元，换手率为1.49%。近日，上海君实生物医药科技股份有限公司发布2026年中期报告，报告期内实现收入约人民币16.96亿元，同比增长45%。核心产品拓益国内销售收入达12.99亿元，同比增长36%。公司银行结余及现金合计约36.70亿元，资金状况充裕。报告期内多项产品获海外上市批准，并与复星万邦等达成授权合作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800023928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","BK1515","BK1583","BK1161","01877","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669646607","title":"君实生物（688180）披露2025年A股股票期权激励计划预留授予公告，9月24日股价下跌2.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669646607","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669646607?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:36","pubTimestamp":1790242580,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，君实生物报收于34.88元，较前一交易日下跌2.52%，最新总市值为358.11亿元。君实生物于近日披露《关于向2025年A股股票期权激励计划激励对象授予预留股票期权的公告》。公告显示，公司于2026年9月23日召开第四届董事会第二十三次会议，确定当日为2025年A股股票期权激励计划的预留授权日，向16名激励对象授予71.50万份股票期权，行权价格为46.67元/股。预留授予的等待期分别为12个月和24个月，行权比例分别为50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400030387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["83130","399300","07233","BK1515","02846","82846","03130","02827","BK0239","BK1147","BK1583","BK1161","01877","BK1610","03188","688180","159982","83188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175879421","title":"君实生物2026年中期营收16.96亿元，经调整净利润1.53亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175879421","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175879421?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:40","pubTimestamp":1790239239,"startTime":"0","endTime":"0","summary":"君实生物发布2026年中期财报，报告期内实现营收16.96亿元，同比增加45%。经调整净利润1.53亿元，较上年同期增加5.66亿元。同期毛利达12.79亿元，同比提升38%。研发投入6.44亿元，占营收约38%，同比下降14%。销售及分销费用5.07亿元，同比增加4%；管理费用2.79亿元，同比增加34%。期内经营活动净现金流出0.63亿元。核心产品特瑞普利单抗上半年国内销售收入达12.99亿元，同比增长36%，在推动营收增长中贡献突出。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"君实生物2026年中期营收16.96亿元，经调整净利润1.53亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":-0.0759},{"period":"1month","weight":-0.0395},{"period":"3month","weight":-0.0754},{"period":"6month","weight":-0.4368},{"period":"1year","weight":-0.3896},{"period":"ytd","weight":-0.2357}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.098181},{"month":2,"riseRate":0.75,"avgChangeRate":0.062525},{"month":3,"riseRate":0.75,"avgChangeRate":0.059343},{"month":4,"riseRate":0.875,"avgChangeRate":0.105939},{"month":5,"riseRate":0.375,"avgChangeRate":-0.021039},{"month":6,"riseRate":0.375,"avgChangeRate":-0.04216},{"month":7,"riseRate":0.625,"avgChangeRate":-0.000677},{"month":8,"riseRate":0.125,"avgChangeRate":-0.039004},{"month":9,"riseRate":0.25,"avgChangeRate":-0.011976},{"month":10,"riseRate":0.25,"avgChangeRate":-0.023318},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}